Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer-from Tumor Development to Therapeutic Implications.

NF-κB signaling chronic inflammation hepatocarcinogenesis hepatocellular carcinoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Jul 2019
Historique:
received: 24 06 2019
revised: 19 07 2019
accepted: 23 07 2019
entrez: 28 7 2019
pubmed: 28 7 2019
medline: 28 7 2019
Statut: epublish

Résumé

Chronic inflammatory cell death is a major risk factor for the development of diverse cancers including liver cancer. Herein, disruption of the hepatic microenvironment as well as the immune cell composition are major determinants of malignant transformation and progression in hepatocellular carcinomas (HCC). Considerable research efforts have focused on the identification of predisposing factors that promote induction of an oncogenic field effect within the inflammatory liver microenvironment. Among the most prominent factors involved in this so-called inflammation-fibrosis-cancer axis is the NF-κB pathway. The dominant role of this pathway for malignant transformation and progression in HCC is well documented. Pathway activation is significantly linked to poor prognostic traits as well as stemness characteristics, which places modulation of NF-κB signaling in the focus of therapeutic interventions. However, it is well recognized that the mechanistic importance of the pathway for HCC is highly context and cell type dependent. While constitutive pathway activation in an inflammatory etiological background can significantly promote HCC development and progression, absence of NF-κB signaling in differentiated liver cells also significantly enhances liver cancer development. Thus, therapeutic targeting of NF-κB as well as associated family members may not only exert beneficial effects but also negatively impact viability of healthy hepatocytes and/or cholangiocytes, respectively. The review presented here aims to decipher the complexity and paradoxical functions of NF-κB signaling in primary liver and non-parenchymal cells, as well as the induced molecular alterations that drive HCC development and progression with a particular focus on (immune-) therapeutic interventions.

Identifiants

pubmed: 31349670
pii: cancers11081053
doi: 10.3390/cancers11081053
pmc: PMC6721782
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Volkswagen Foundation
ID : Lichtenberg Program
Organisme : Wilhelm Sander-Stiftung
ID : 2017.007.1
Organisme : Deutsche Forschungsgemeinschaft
ID : MA 4443/2-2; SFB1292
Organisme : Universitätsmedizin Mainz TransMED
ID : TransMED Clinician Scientist Program

Références

Science. 1999 Apr 9;284(5412):321-5
pubmed: 10195897
Immunity. 1999 Apr;10(4):421-9
pubmed: 10229185
J Exp Med. 1999 Jun 7;189(11):1839-45
pubmed: 10359587
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11848-53
pubmed: 10518539
Oncogene. 1999 Nov 22;18(49):6853-66
pubmed: 10602461
Genes Dev. 2000 Apr 1;14(7):854-62
pubmed: 10766741
Nature. 2001 Nov 15;414(6861):313-7
pubmed: 11713531
Nat Rev Cancer. 2002 Apr;2(4):301-10
pubmed: 12001991
J Immunol. 2002 Aug 1;169(3):1319-25
pubmed: 12133954
Trends Biochem Sci. 2004 Feb;29(2):72-9
pubmed: 15102433
Nature. 2004 Sep 23;431(7007):461-6
pubmed: 15329734
Gastroenterology. 2005 Jan;128(1):108-20
pubmed: 15633128
Nat Med. 2005 Feb;11(2):191-8
pubmed: 15685170
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
Cancer Lett. 2005 Mar 10;219(2):205-13
pubmed: 15723721
Cell. 2005 Jul 1;121(7):977-90
pubmed: 15989949
Int J Oncol. 2006 Apr;28(4):923-30
pubmed: 16525642
J Immunol. 2006 Apr 1;176(7):4173-81
pubmed: 16547254
Nature. 2006 May 25;441(7092):431-6
pubmed: 16724054
Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10544-51
pubmed: 16807293
Int J Oncol. 2006 Sep;29(3):713-9
pubmed: 16865289
Annu Rev Med. 2007;58:267-84
pubmed: 17002552
Liver Int. 2006 Dec;26(10):1163-74
pubmed: 17105581
Cancer Cell. 2007 Feb;11(2):119-32
pubmed: 17292824
Am J Physiol Gastrointest Liver Physiol. 2007 Sep;293(3):G631-9
pubmed: 17640975
Hepatology. 2007 Aug;46(2):590-7
pubmed: 17661407
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Biomed Pharmacother. 2008 Jul-Aug;62(6):366-72
pubmed: 17988825
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
J Exp Med. 2008 Jun 9;205(6):1261-8
pubmed: 18490490
Gastroenterology. 2008 Sep;135(3):956-68
pubmed: 18555021
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9733-8
pubmed: 18606991
EMBO Rep. 2008 Oct;9(10):1048-54
pubmed: 18704119
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
N Engl J Med. 2008 Nov 6;359(19):1995-2004
pubmed: 18923165
Cancer Cell. 2008 Nov 4;14(5):408-19
pubmed: 18977329
Mol Pharmacol. 2009 Aug;76(2):290-300
pubmed: 19461054
Hepatology. 2009 Oct;50(4):1251-62
pubmed: 19670424
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14978-83
pubmed: 19706447
Cancer Res. 2009 Sep 15;69(18):7385-92
pubmed: 19723656
Gastroenterology. 2010 Jan;138(1):347-59
pubmed: 19782079
Cancer Cell. 2009 Oct 6;16(4):295-308
pubmed: 19800575
Cancer Cell. 2010 Mar 16;17(3):286-97
pubmed: 20227042
Cancer Cell. 2010 May 18;17(5):481-96
pubmed: 20478530
Anat Rec (Hoboken). 2010 Sep;293(9):1492-6
pubmed: 20652939
Clin Immunol. 2011 Jan;138(1):41-9
pubmed: 20940109
Cell Res. 2011 Jan;21(1):159-68
pubmed: 21187858
Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):108-18
pubmed: 21293511
Carcinogenesis. 2011 Sep;32(9):1372-80
pubmed: 21325634
J Hepatol. 2012 Jan;56(1):267-75
pubmed: 21782758
Gastroenterology. 2011 Dec;141(6):2176-87
pubmed: 21878202
Hum Pathol. 2012 Jul;43(7):1012-9
pubmed: 22176836
Gastroenterology. 2012 Apr;142(4):1021-1031.e15
pubmed: 22178589
Cancer Lett. 2012 Sep 1;322(1):35-44
pubmed: 22343223
Curr Opin Gastroenterol. 2012 May;28(3):266-72
pubmed: 22395571
Hepatology. 2012 Sep;56(3):1117-28
pubmed: 22407857
Immunol Rev. 2012 Mar;246(1):379-400
pubmed: 22435567
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
Hepatology. 2012 Nov;56(5):1792-803
pubmed: 22707408
Gastroenterology. 2012 Oct;143(4):1084-94.e7
pubmed: 22749933
Nat Rev Cancer. 2012 Jul 05;12(8):508-9
pubmed: 22763663
In Vivo. 2012 Jul-Aug;26(4):671-81
pubmed: 22773582
Clin Sci (Lond). 2013 Feb;124(4):279-87
pubmed: 22970906
Hepatology. 2013 Feb;57(2):817-28
pubmed: 22996371
Gastroenterology. 2013 Apr;144(4):829-40
pubmed: 23295441
Gastroenterology. 2013 Mar;144(3):512-27
pubmed: 23313965
Asian Pac J Cancer Prev. 2012;13 Suppl:101-5
pubmed: 23480751
Cell Death Differ. 2013 Nov;20(11):1580-92
pubmed: 23933814
Surgery. 2013 Sep;154(3):468-78
pubmed: 23972653
Nature. 2013 Sep 19;501(7467):328-37
pubmed: 24048065
Oncol Rep. 2014 Apr;31(4):1911-20
pubmed: 24573111
Int J Oncol. 2014 Jul;45(1):177-88
pubmed: 24807012
Cell Death Differ. 2014 Nov;21(11):1721-32
pubmed: 24971483
Cancer Cell. 2014 Sep 8;26(3):331-343
pubmed: 25132496
Hepatology. 2015 Jan;61(1):191-9
pubmed: 25142309
PLoS One. 2014 Aug 29;9(8):e106056
pubmed: 25170898
J Hepatobiliary Pancreat Sci. 2015 Feb;22(2):94-100
pubmed: 25181580
Cancer Immunol Res. 2014 Sep;2(9):823-30
pubmed: 25187272
Amino Acids. 2014 Dec;46(12):2809-22
pubmed: 25245054
Mol Cancer. 2015 Jan 27;14:10
pubmed: 25622857
Int J Oncol. 2015 May;46(5):2021-8
pubmed: 25673177
Science. 2015 Feb 13;347(6223):729-31
pubmed: 25678653
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Oncotarget. 2015 Mar 30;6(9):6627-40
pubmed: 25749383
J Hepatol. 2015 Sep;63(3):661-9
pubmed: 25937435
BMC Cancer. 2015 May 07;15:368
pubmed: 25947641
Nat Rev Cancer. 2015 Nov;15(11):653-67
pubmed: 26493646
Nat Immunol. 2015 Dec;16(12):1235-44
pubmed: 26502405
Biomed Res Int. 2015;2015:363671
pubmed: 26539482
Cancer Cell. 2015 Nov 9;28(5):582-598
pubmed: 26555174
Cancer Res. 2016 Jan 15;76(2):239-50
pubmed: 26567141
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2016 Jun;63(6):1888-99
pubmed: 26844528
Hepatology. 2016 May;63(5):1592-607
pubmed: 26892811
J Immunol. 2016 Apr 1;196(7):2933-8
pubmed: 26903482
Hepatology. 2016 Jul;64(1):295-7
pubmed: 27122117
Autophagy. 2016 Jun 2;12(6):999-1014
pubmed: 27124102
Dig Dis. 2016;34(4):429-37
pubmed: 27170398
Sci Rep. 2016 Jun 13;6:27853
pubmed: 27290989
Sci Rep. 2016 Aug 30;6:32167
pubmed: 27571770
FEBS J. 2016 Oct;283(20):3839-3850
pubmed: 27616304
Biofactors. 2017 Jan 2;43(1):63-72
pubmed: 27628030
Oncotarget. 2017 Jan 17;8(3):4543-4548
pubmed: 27965464
Oncol Rep. 2017 Feb;37(2):1036-1044
pubmed: 28000898
Cancer Cell. 2017 Jan 9;31(1):94-109
pubmed: 28017612
Cell Rep. 2017 Mar 14;18(11):2780-2794
pubmed: 28297679
J Biochem Mol Toxicol. 2017 Aug;31(8):null
pubmed: 28346727
Oncotarget. 2017 Jul 25;8(30):48688-48700
pubmed: 28415775
Oncol Rep. 2017 Aug;38(2):899-907
pubmed: 28627705
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Immunity. 2017 Sep 19;47(3):450-465.e5
pubmed: 28889947
Hepatology. 2018 Feb;67(2):636-650
pubmed: 28913935
World J Gastroenterol. 2017 Oct 7;23(37):6802-6816
pubmed: 29085224
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
J Hepatol. 2018 Jul;69(1):237-247
pubmed: 29505843
Front Immunol. 2018 Mar 19;9:546
pubmed: 29616037
Oncol Res Treat. 2018;41(5):292-297
pubmed: 29705790
Biomed Pharmacother. 2018 Mar;99:939-946
pubmed: 29710494
Toxicol Lett. 2018 Oct 1;295:32-40
pubmed: 29859236
Cell Physiol Biochem. 2018;47(3):1152-1166
pubmed: 29913454
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell Metab. 2019 Jan 8;29(1):18-26
pubmed: 30449681
Cell. 2018 Nov 15;175(5):1289-1306.e20
pubmed: 30454647
J Hepatol. 2019 Apr;70(4):674-683
pubmed: 30543829
Mol Ther Oncolytics. 2018 Dec 14;12:112-123
pubmed: 30719501
Target Oncol. 2019 Apr;14(2):115-123
pubmed: 30805831
Cancer Cell. 2019 May 13;35(5):714-720
pubmed: 31085174
Cancer Lett. 2019 Aug 28;458:113-122
pubmed: 31128214
Science. 1996 Nov 1;274(5288):782-4
pubmed: 8864118

Auteurs

Carolin Czauderna (C)

Department of Medicine I, Lichtenberg Research Group for Molecular Hepatocarcinogenesis, University Medical Center of the Johannes Gutenberg University of Mainz, 55131 Mainz, Germany.

Darko Castven (D)

Department of Medicine I, Lichtenberg Research Group for Molecular Hepatocarcinogenesis, University Medical Center of the Johannes Gutenberg University of Mainz, 55131 Mainz, Germany.

Friederike L Mahn (FL)

Department of Medicine I, Lichtenberg Research Group for Molecular Hepatocarcinogenesis, University Medical Center of the Johannes Gutenberg University of Mainz, 55131 Mainz, Germany.

Jens U Marquardt (JU)

Department of Medicine I, Lichtenberg Research Group for Molecular Hepatocarcinogenesis, University Medical Center of the Johannes Gutenberg University of Mainz, 55131 Mainz, Germany. marquarj@uni-mainz.de.

Classifications MeSH